Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Teleflex IncorporatedNYSE: TFX

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of $99.69M fell 18.7% year over year, ahead of the -267.2% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -45.6% a year.

Context

  • Net income amounted to 2.9% of revenue in FY2025, up 0.7 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of $343.28M (+486.5%) for the fiscal year ending Dec 2026, a step up from the -16.0% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$99.69M+1322.6% QoQ
Last fiscal yearDec 2025
$58.53M-16.0% YoY
LTMJun 2026
-$320.9M-267.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.7%+119.4%+138.1 pp
1 year-16.0%+486.5%+502.5 pp
3-year CAGR-45.6%+97.0%+142.6 pp
5-year CAGR+62.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
58.53M USD
Year-over-year change
-16.0%
4-year CAGR
-41.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -267.2% is the 10th highest of 11, against a peer median of -21.5%.
  • Net income amounts to 12.3% of revenue for TFX, versus a peer median of 11.8%.
TFX Competitors
Net Income for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$1.38B USD+152.9%+50.8%—
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$717.13M USD-2481.4%+50.8%159.1%
CRSPCRISPR Therapeutics AGLTM Sep 2026$456.14M USD-6.6%-3.6%1812.1%
TFXTeleflex IncorporatedLTM Jun 2026$320.9M USD-267.2%-45.6%12.3%
KRYSKrystal Biotech, Inc.LTM Jun 2026$241.47M USD+64.6%—54.8%
STVNStevanato Group S.p.A.LTM Jun 2026€173.64M EUR-3.3%-10.5%14.2%
BLCOBausch + Lomb CorporationLTM Jun 2026$167M USD-36.5%—3.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$160.12M USD+35.2%+19.9%9.9%
TGTXTG Therapeutics, Inc.LTM Sep 2026$106.06M USD-76.3%—11.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$38.38M USD-106.1%—3.8%
ALKSAlkermes plcLTM Sep 2026$351K USD-100.1%—0.0%
Peer median (excluding TFX) —-21.5%+19.9%11.8%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income485.37M363.14M356.33M69.68M58.53M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
Deferred Income Tax(110.24M)(13.01M)(13.05M)0(100.97M)
Stock-Based Compensation22.94M27.22M31.47M31.35M0
Change in Working Capital127.35M(239.96M)(111.77M)(1.82M)(81.09M)
Accounts Receivables(600K)(38.46M)(15.76M)(27.95M)(85.53M)
Inventory(11.14M)(110.69M)(41.07M)1.72M84.04M
Accounts Payables94.02M(24.79M)(31.26M)9.67M(8.28M)
Other Working Capital45.06M(66.03M)(23.68M)14.74M(71.31M)
Other Non-Cash Items(111.36M)(25.84M)5.55M261.94M286.46M
Operating Cash Flow651.42M342.14M510.64M635.74M340.68M
Capital Expenditures(71.62M)(79.19M)(91.44M)(126.43M)(95.24M)
Acquisitions (Net)220.32M(186M)(588.92M)(120K)(825.15M)
Purchases of Investments(18.42M)(22.3M)(11.3M)(7.3M)(5M)
Sales of Investments7.3M7.3M7.3M7.3M0
Other Investing Activities19.15M22.24M63.13M27.2M76.19M
Investing Cash Flow156.74M(257.94M)(621.23M)(99.36M)(849.19M)
Debt Repayment(634.5M)(145.45M)101.25M(161.5M)982.04M
Common Stock Issued11.1M4.31M000
Common Stock Repurchased0(4.31M)0(200M)(300M)
Dividends Paid(63.65M)(63.79M)(63.9M)(63.54M)(60.27M)
Other Financing Activities(28.77M)(8.27M)1.19M3.12M(10.23M)
Financing Cash Flow(715.82M)(217.51M)38.54M(421.93M)611.54M
Effect of Forex Changes(23.13M)(19.74M)2.86M(9.65M)(29.35M)
Net Change in Cash69.2M(153.05M)(69.19M)104.8M73.68M
Free Cash Flow579.8M262.95M419.2M509.31M245.44M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.